Eltrombopag, marketed under brand names including Promacta (in the United States) and Revolade (internationally), is an oral thrombopoietin receptor agonist used to treat thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) and severe aplastic anemia. As a highly valued pharmaceutical product with a global market projected to expand from USD 2.68 billion in 2025 to USD 4.22 billion by 2031, understanding the landscape of global buyers is essential for suppliers, manufacturers, and distributors seeking to expand their market presence. This comprehensive guide provides pharmaceutical suppliers with actionable intelligence on Eltrombopag buyers worldwide, including key importers, distributors, and procurement channels across major markets. Understanding the Eltrombopag Global Market Market Overview and…